Habits
Health Screenings in Your 50s
US guidance in your 50s adds lung CT for eligible current or former smokers and a PSA decision from 55; bone testing depends on menopause and fracture risk.
Your 50s bring a few new screening tests and a longer list of ones that simply continue. Humanic Blue’s guide also takes up the question “should I get tested for everything?” in a decade when a clinic or app may offer to do exactly that.
The US Preventive Services Task Force (USPSTF) adds two age milestones: yearly low-dose CT scans of the lungs from 50 for people with the specified smoking history, and an individual decision about prostate-specific antigen (PSA) blood testing for men from 55. It also recommends bone-density testing after menopause for women under 65 whose fracture risk is increased; that can begin before the 50s.
Other screening continues according to age, anatomy and risk. The USPSTF recommends against several tests in people without symptoms, including routine screening for ovarian, pancreatic and thyroid cancer. For living longer and better, the distinction is between a test that can improve a defined health outcome and one that merely finds more abnormalities.
Key Takeaways
- USPSTF lung-screening eligibility begins at 50 and its individual PSA decision at 55. Risk-based bone screening after menopause may already apply.
- USPSTF guidance also covers ongoing colorectal, breast, cervical, blood-pressure, diabetes, heart-risk and mental-health checks, with different eligibility rules.
- A USPSTF D grade means the Task Force recommends against a test for the population it reviewed.
- Cancer screening can reduce deaths from the cancer it targets. A 2023 review did not establish an overall lifespan gain for most tests it examined.
The ledger at a glance
| Status | Screening | Who | Grade |
|---|---|---|---|
| Start | Low-dose CT for lung cancer, yearly | Ages 50–80, at least 20 pack-years (explained below), smoking now or quit within 15 years | B |
| Start | PSA screening decision | Men 55–69 | C (individual decision) |
| Risk-based | Bone density | Postmenopausal women under 65 at increased risk | B |
| Continue | Colorectal cancer | Ages 45–75 | A (50–75) |
| Continue | Mammogram every 2 years | Women 40–74 | B |
| Continue | Cervical cancer | People with a cervix, to 65 | A |
| Continue | Blood pressure | All adults | A |
| Continue | Prediabetes and type 2 diabetes | USPSTF: ages 35–70 with overweight or obesity; American Diabetes Association (ADA): everyone by 35 | B (USPSTF population) |
| Continue | Eligibility for cholesterol-lowering statin medication | Ages 40–75 with a risk factor and 10-year cardiovascular risk of 10% or more | B |
| Continue | Depression; anxiety | All adults; anxiety to 64 | B |
| Continue | HIV once; hepatitis C once | HIV to 65; hepatitis C to 79 | A; B |
| Ask | Hepatitis B, syphilis, tuberculosis infection without active illness | People at increased risk | A/B |
| USPSTF recommends against | Ovarian, pancreatic, thyroid cancer; neck-artery narrowing; chronic obstructive pulmonary disease (COPD) | People without symptoms in the populations reviewed; high-risk exclusions vary | D |
Grades are from the USPSTF A and B list and the individual statements linked below. A grade A or B means the USPSTF recommends the service; C means offer it selectively; D means recommend against.
Who qualifies for lung cancer screening at 50?
The USPSTF lung cancer recommendation covers “adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.” A pack-year is one pack a day for a year, so 20 pack-years could be a pack a day for 20 years or two packs a day for 10. The test is a yearly low-dose CT scan.
The USPSTF recommendation does not cover people who have never smoked or fall outside its age and smoking thresholds. It also recommends stopping screening when health problems substantially limit life expectancy or the ability or willingness to have lung surgery intended to cure the cancer.
Start: the PSA decision for men
For men 55 to 69, the current final USPSTF recommendation calls for an individual PSA decision after discussing benefits and harms; an update is in progress. The trade-offs, including finding a cancer that would never cause illness (overdiagnosis) and the harms of treatment, are covered in Prostate Health as You Age. The 2023 American Urological Association guideline says clinicians should offer screening at 40 to 45 to people at increased risk because of Black ancestry, an inherited gene change or a strong family history. That is separate from the USPSTF’s average-risk age range.
How do detection, overdiagnosis and deaths prevented enter the same PSA discussion?
Bone density after menopause: risk determines timing
The USPSTF’s 2025 osteoporosis recommendation covers postmenopausal women younger than 65 who are at increased fracture risk on a clinical risk assessment. Screening for all women starts at 65. For men, the USPSTF found the evidence insufficient. Who counts as increased risk is covered in When Should Women Get a Bone Density Test?.
Which screenings carry over from your 40s?
The USPSTF recommendations described in the 40s guide generally continue, subject to each test’s eligibility rules:
- Colorectal cancer screening continues from 45 through 75, by stool test or colonoscopy at the recommended interval.
- Mammograms every two years continue from 40 through 74.
- Cervical screening continues to 65 for people with a cervix.
- Blood pressure, diabetes screening and cardiovascular risk stay on the list. The USPSTF recommends diabetes screening at ages 35 to 70 for people with overweight or obesity; the ADA’s 2026 standard says screening should begin by 35 for everyone else too. The USPSTF recommends a statin for adults 40 to 75 with at least one risk factor and an estimated 10-year cardiovascular risk of 10% or more.
- Depression screening continues, and anxiety screening is recommended through 64.
How each works, and the options within them, is covered in What Health Screenings Do You Need in Your 40s?
Which screenings does the USPSTF recommend against?
The USPSTF recommends against the following screening tests for the populations described:
- Ovarian cancer: against screening asymptomatic people without a known high-risk hereditary syndrome (2018).
- Pancreatic cancer: against screening asymptomatic adults (2019).
- Thyroid cancer: against screening asymptomatic adults (2017).
- Carotid artery narrowing: against screening the general adult population (2021).
- Chronic obstructive pulmonary disease (COPD), a group of lung conditions that obstruct airflow: against screening asymptomatic adults (2022).
A D grade means the USPSTF found that the harms, such as false alarms, further testing and treatment of harmless findings, equal or outweigh the benefits. Symptoms require diagnostic assessment rather than screening. Some high-risk groups also fall outside the populations reviewed; each recommendation defines its own scope.
Does screening help you live longer?
This is the question behind most screening decisions, and the answer is narrower than many people expect. A 2023 meta-analysis in JAMA Internal Medicine, led by Michael Bretthauer of the University of Oslo, pooled randomized trials of six common cancer screening tests in more than 2.1 million people. It examined deaths from all causes, not just deaths from the cancer each test targets.
Only sigmoidoscopy, an examination of the lower colon, showed a clear gain in estimated lifetime in that analysis. For mammography, PSA testing, colonoscopy, stool blood testing and lung CT, uncertainty was too great to establish a gain in overall lifetime. That is a limit of what these trials established, not proof that the tests add no time. The estimates and follow-up periods are below in Extra Insights & Sources.
That does not mean screening lacks benefit. Recommended tests can reduce deaths from the cancers they target, while all-cause mortality combines deaths a screening test could affect with many it cannot. One reviewer extracted the trial data, and the trials differed in their populations, screening schedules and follow-up periods. Its result is a reason to weigh each test on its own disease-specific benefits and harms, not proof that screening as a whole is ineffective.
How does disease-specific mortality differ from all-cause mortality when judging a screening benefit?
What’s Interesting
The screening list in your 50s is as much about what’s left off as what’s on it. The USPSTF recommends against routine screening of the pancreas, thyroid or neck arteries in the populations it reviewed. And the tests that are recommended reduce deaths from specific cancers more clearly than they extend overall life. That tension is why the USPSTF uses grades, and why a C grade like the PSA decision leaves the choice to the patient.
What This Means in Practice
The age and risk distinctions in these guidelines identify several questions for a conversation about living longer and better:
- Bring your smoking history in pack-years to see if lung screening applies.
- Which PSA guidance applies? The USPSTF describes an individual decision at 55–69; the American Urological Association recommends an earlier offer of screening for people at increased risk, including Black ancestry, inherited gene changes or a strong family history.
- Does fracture-risk assessment change bone-screening timing? The USPSTF recommends risk-based screening for postmenopausal women under 65.
- Check you’re up to date on colorectal, breast and cervical screening, and when each is next due.
- Know your numbers: blood pressure, cholesterol, 10-year cardiovascular risk and diabetes risk.
- Question extra tests that aren’t on the list. Ask what decision the result would change.
- Report symptoms rather than waiting for a screening interval.
A primary care clinician can tailor the list to your history. Before 65, check your plan’s preventive benefits. HealthCare.gov says these services are “generally” covered “at no cost to you when provided by an in-network medical provider,” though “$0 cost isn’t guaranteed in all cases.”
Bottom Line
USPSTF guidance adds lung CT eligibility from 50 for current or former smokers who meet its criteria, and a PSA discussion for men from 55. Risk-based bone-density testing after menopause may already apply before this decade. Colorectal, breast, cervical, blood pressure, diabetes, cardiovascular and mental health screening continue. The USPSTF recommends against screening people without symptoms for ovarian, pancreatic and thyroid cancer, carotid narrowing and COPD. Screening reduces deaths from specific cancers, but a large meta-analysis found little evidence that most tests extend overall life, so each test deserves its own decision. Age alone does not settle these decisions: smoking history, anatomy, earlier results, family history and the likely consequences of an abnormal test all affect the discussion.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01Which part of this guide feels easiest to turn into a better question for a routine visit?
- 02Where do you still feel the line is blurry between a useful check and more testing than you need?
- 03What would make the next conversation clearer: timing, eligibility, possible harms, or what happens after an abnormal result?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
- USPSTF lung-screening eligibility begins at 50 and the PSA decision at 55; risk-based bone screening after menopause can begin earlier. Established guideline recommendations.
- Colorectal, breast and cervical screening continue on established schedules. Established.
- The USPSTF recommends against ovarian, pancreatic, thyroid, carotid and COPD screening in people without symptoms. Established.
- Common cancer screening tests reduce deaths from their target cancers. Supported.
What We Don’t Know
- Whether most cancer screening tests extend overall lifespan. Uncertain; trials have mostly been too small to show it.
- How new blood-based multi-cancer tests fit in. Unknown; no such test is FDA-authorized, and randomized trials have not established a mortality benefit.
- How pending USPSTF updates, including prostate screening, will change the list. Uncertain.
Sources
- USPSTF, A and B Recommendations: supports the screening populations and grades in the ledger; grades describe net benefit for defined populations, not an individual guarantee.
- USPSTF, Lung Cancer: Screening (2021): supports annual low-dose CT at ages 50–80 for people with at least 20 pack-years who smoke or quit within 15 years.
- USPSTF, Prostate Cancer: Screening (2018 current final recommendation): supports an individual PSA decision at 55–69 and no routine screening at 70 or older; an update is in progress.
- AUA/SUO, Early Detection of Prostate Cancer Guideline (2023 professional guideline): supports offering screening at 40–45 to people with Black ancestry, germline mutations or strong family history; this is a separate high-risk pathway.
- USPSTF, Osteoporosis to Prevent Fractures: Screening (2025): supports screening all women at 65, younger postmenopausal women at increased risk and the insufficient-evidence finding for men.
- American Diabetes Association, Standards of Care in Diabetes—2026: supports screening all other adults by 35 and at least every three years after a normal result, with earlier risk-based testing.
- USPSTF, Ovarian Cancer Screening Recommendation (2018): supports recommending against screening asymptomatic people without a known high-risk hereditary syndrome.
- USPSTF, Pancreatic Cancer Screening Recommendation (2019): supports recommending against screening asymptomatic adults.
- USPSTF, Thyroid Cancer Screening Recommendation (2017): supports recommending against screening asymptomatic adults.
- USPSTF, Asymptomatic Carotid Artery Stenosis Screening Recommendation (2021): supports recommending against population screening.
- USPSTF, COPD Screening Recommendation (2022): supports recommending against screening asymptomatic adults; symptoms require diagnostic evaluation instead.
- Bretthauer et al., Estimated Lifetime Gained With Cancer Screening Tests (JAMA Internal Medicine, 2023; meta-analysis of randomized trials, 2,111,958 participants): reports an estimated 110-day lifetime gain for sigmoidoscopy, with uncertainty from no gain to about 274 days, and estimates too uncertain to establish gains for five other tests. Median follow-up was 10 years for lung CT, PSA testing and colonoscopy, 13 for mammography, and 15 for sigmoidoscopy and stool blood testing; single data extraction and heterogeneous programs limit interpretation, and disease-specific mortality remains separate.
- National Cancer Institute, Questions and Answers About Multi-Cancer Detection Tests: supports that no MCD test is FDA-authorized and randomized trials have not established clinical benefit.
- HealthCare.gov, Preventive Health Services: supports the qualified coverage statement; no-cost coverage is generally tied to plan rules and in-network care and is not guaranteed in every case.
Related product and service comparisons
The companion comparison distinguishes commercial MRI packages from a multi-cancer blood test, including coverage and follow-up limits.
Photo credits
Images from Pexels.
- featured: Photo by Los Muertos Crew — original Pexels photo.
- inline-1: Photo by Tima Miroshnichenko — original Pexels photo.
- inline-2: Photo by https://kaboompics.com/ — original Pexels photo.
Leave a Reply